However, while modulating STING has shown promise against primary and metastatic cancers in pre-clinical studies, STING agonists have demonstrated limited anti-tumor efficacy in the clinical trials conducted so far, even when combined with PD-1/PD-L1 ICB (32–34). Here, STING1 is linked to metastatic malignant neoplasm.